Introduction {#s1}
============

Pancreatic adenocarcinoma (PDAC) is the seventh leading cause of death in cancer patients ([@B1]), and locally advanced pancreatic cancer (LAPC) accounts for \~40% of all PDAC cases. Despite currently available therapies, the 5-year overall survival (OS) rate of LAPC patients was only 3% and the median OS were only 11 months ([@B2]). Palliative chemotherapy remains the recommended therapy for patients with LAPC. However, progression of the primary tumor contributes to more than 30% of deaths and the rate of downstaging is only 4--15%, which suggests the need for novel local control approaches ([@B2], [@B3]).

Irreversible electroporation (IRE) is a novel ablative and non-thermal method ([@B4]). IRE was shown to be a suitable treatment for LAPC that encases surrounding vessels because its unique features are not sensitive to the heat sink effect ([@B5], [@B6]). Although the role of concurrent IRE and conventional treatment has been discussed in previous studies, these studies were mostly based on small cohorts of patients and had contradictory results ([@B7], [@B8]). Moreover, prospective data for combination therapy of IRE and chemotherapy in clinical trials is still lacking. It is necessary to fill this gap with new information on the clinical and treatment characteristics of a large cohort of patients with LAPC. In this study, the Surveillance, Epidemiology, and End Results (SEER) database and a study cohort from Sun Yat-sen University Cancer Center (SYSUCC) were adopted to evaluate the efficacy of combination therapy with IRE and chemotherapy in patients with LAPC.

Materials and Methods {#s2}
=====================

Patients
--------

The first cohort of patients with LAPC was from the SEER database (2012--2015) of the United States (US) National Cancer Institute, which provided data on cancer incidence and survival in the US and covered 30% of the population. Patients with the following information were included in this study: International Classification of Diseases for Oncology, Third Edition (ICD-O-3) site codes C25.1, C25.2, C25.3, and C25.8. All included patients had pathologically confirmed pancreatic adenocarcinoma or infiltrating ductal carcinoma (ICD-O-3 histology codes 8140/3 and 8500/3, respectively). Only patients who were without distant metastases and whose tumor were classified as T4 were included. The SYSUCC cohort consisted of patients who were initially treated with chemotherapy alone or induction chemotherapy followed by IRE from August 2015 to August 2017. The inclusion criteria were as follows: (1) pathologically confirmed pancreatic adenocarcinoma and radiologically confirmed LAPC. LAPC was defined per the seventh edition of the AJCC staging system for pancreatic cancer, which describes LAPC as arterial encasement of either the celiac axis or superior mesenteric artery or unreconstructable superior mesenteric or portal vein involvement, with no evidence of metastatic disease from abdominal and thoracic computed tomography (CT) ([@B9], [@B10]); (2) four months of induction chemotherapy \[FOLFIRINOX or gemcitabine (GEM)-based chemotherapy\] without radiotherapy. The following exclusion criteria were adopted: (1) second primary cancer; (2) distant metastases; (3) other treatments, including surgical resection or radiofrequency ablation (RFA); (4) an Eastern Cooperative Oncology Group performance status (ECOG PS) score larger than 2; and (5) missing or incomplete information.

Data Collection
---------------

The SEER database and the medical management system of SYSUCC were used to extract the demographic, clinical, and pathological variables of patients, including age at diagnosis, gender, tumor site, grade and size, tumor-node-metastasis (TNM) stage, ECGO PS score, chemotherapy, radiotherapy, IRE treatment, and cause of death. In addition, other clinical factors, including white blood cell (WBC) count, hemoglobin (HGB), platelet (PLT) count, serum levels of alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyltranspeptidase (GGT), albumin (ALB), total bilirubin (TBIL), indirect bilirubin (IBIL), C-reactive protein (CRP), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), which were the same as those in our previous reports ([@B11]), were also investigated in this study. The endpoints were OS, cancer-specific survival (CSS), and progression-free survival (PFS), which were defined as the duration from the date of treatment to death from all causes, cancer-related deaths, and tumor progression, respectively, or last follow-up. September 30, 2018 was the last date of follow-up.

Treatment Procedure
-------------------

Induction chemotherapy of either FOLFIRINOX or GEM-based chemotherapy was used for a duration of 4 months (totaling 3 cycles of GEM-based chemotherapy or 4--6 cycles of FOLFIRINOX-based chemotherapy), which was in accordance with previous studies ([@B12], [@B13]). The same line of chemotherapy was performed 7--14 days after IRE treatment. Patients who did not receive IRE treatment received FOLFIRINOX or GEM-based chemotherapy as the standard treatment. The same procedure of IRE which was reported in our previous research was adopted in the present study ([@B11]). During the procedure of IRE, two to six probes will be used according to the size and location of the tumor to create an electric field around the tumor, which will finally cause nanoscale pore formation in the plasma membrane. The generator unit software is used to analysis the probe configuration data of ultrasound and provides optimal voltage and pulse length delivery. A setting of 1,500 V/cm is often used as initial setting, with a planned delivery of 90 pulses at a pulse length of 70--90 ms. Simply, this procedure was similar with the proposed procedure suggested by Martin et al., which was also adopted in cases of SEER database ([@B14], [@B15]).

Follow-Up
---------

Regular follow-up data was available for each patient: 1 month after IRE for the initial follow-up, and every 2--3 months thereafter. Abdominal CT or MRI, physical examination, and serum CA19-9 and CEA analyses were performed for each follow-up.

Statistical Analysis
--------------------

Continuous and categorical variables were compared by student\'s *t*-test and chi-square test, respectively. The Kaplan-Meier method was used to analyze OS and PFS and the log-rank test was used to compare the survival differences. The cumulative incidence function (CIF) of the variables on cancer- and non-cancer-specific mortality was evaluated by Fine and Gray\'s model ([@B16], [@B17]). Multivariate analysis was performed using the Cox regression model for variables that were significantly associated with OS, CSS, and PFS in the univariate analysis, to determine the prognostic factors of survival with 95% confidence intervals (CIs) and a significance level of 0.05. Balanced variables were selected by a logistic regression model with propensity score matching (PSM) analysis. One-to-fifteen and one-to-two nearest-neighbor matching algorithms were used in the SEER and SYSUCC databases, respectively ([@B18]). PSM results were also reported as effect size: \|value\| \< 0.2 indicated a negligible difference, \|value\| \< 0.5 indicated a small difference, \|value\| \< 0.8 indicated a moderate difference, and any other value indicated a large difference ([@B19], [@B20]). R statistical software (R software version 3.4.2; R Foundation for Statistical Computing, Vienna, Austria) was used to perform all statistical analyses.

Results {#s3}
=======

Patient Characteristics
-----------------------

The flow diagram for data selection is shown in [Figure 1](#F1){ref-type="fig"}. In total, 3,515 patients with LAPC from SEER database, including 3,348 patients who received chemotherapy only and 167 patients who received combination therapy with IRE and chemotherapy, were included in this study. The baseline clinical and pathological characteristics were compared between the two groups ([Table 1](#T1){ref-type="table"}). The median age was 65 years (range, 26--97 years) and 67 years (range, 29--96 years) for patients in the combination therapy group and chemotherapy group, respectively. More than half of the tumors were located in the head of the pancreas in both groups. Compared with patients in the combination therapy group, significantly more patients in the chemotherapy group underwent radiotherapy. To equilibrate significantly different baseline characteristics, 167 patients in the combination therapy group and 2,505 matched patients in the chemotherapy group were selected. All variables were balanced after the PSM analysis.

![Flow diagram of the data selection process.](fonc-10-00006-g0001){#F1}

###### 

Comparisons of clinical and imaging characteristics of patients.

  **Characteristic**   **Before PSM**   **After PSM**   **Effect size**                                                   
  -------------------- ---------------- --------------- ----------------- ------- --------- ----- ------- ------- ------- --------
  **SEER DATASET**                                                                                                        
  Total number                          167             3,348             3,515             167   2,505   2,672           
  Age (years)          ≤60              51              946               997     0.538     51    681     732     0.370   0.002
                       \>60             116             2,402             2,518             116   1,824   1,940           
  Gender               Female           78              1,665             1,743   0.476     78    1,251   1,329   0.425   0.001
                       Male             89              1,683             1,772             89    1,254   1,343           
  Race                 Black            16              458               474     0.088     16    351     387     0.084   0.005
                       White            141             2,583             2,724             141   1,929   2,070           
                       Others           10              307               317               10    225     235             
  Tumor size (cm)      ≤2               7               120               127     0.778     7     91      98      0.808   0.021
                       2\~4             71              1,508             1,579             71    1,124   1,195           
                       \>4              89              1,720             1,809             89    1,290   1,379           
  Tumor grade          Well             15              174               189     0.058     15    140     155     0.051   0.016
                       Moderate         74              1,522             1,596             74    1,094   1,168           
                       Poor             78              1,652             1,730             78    1,271   1,349           
  LN metastasis        Absent           119             2,189             2,308   0.133     119   1,654   1,773   0.177   0.007
                       Present          48              1,159             1,207             48    851     899             
  Tumor site           Head             84              1,799             1,883   0.473     84    1,352   1,436   0.547   0.024
                       Body             53              1,057             1,110             53    772     825             
                       Tail             30              492               522               30    381     411             
  Radiotherapy         No               127             2,119             2,246   0.001     127   1,870   1,897   0.783   0.156
                       Yes              40              1,229             1,269             40    635     675             
  **SYSUCC DATASET**                                                                                                      
  Total number                          36              96                132               36    36      72              
  Age (years)          ≤60              20              52                72      0.887     20    20      40      1.000   0.032
                       \>60             16              44                60                16    16      32              
  Gender               Female           17              71                88      0.006     17    24      41      0.153   0.146
                       Male             19              25                44                19    12      31              
  Tumor size (cm)      ≤2               1               9                 10      0.061     1     1       2       0.256   0.032
                       2\~4             20              34                54                20    13      33              
                       \>4              15              53                68                15    22      37              
  Tumor grade          Well             3               1                 4       0.092     3     1       4       0.588   0.047
                       Moderate         20              56                76                20    21      41              
                       Poor             13              39                52                13    14      27              
  LN metastasis        Absent           29              31                60      \<0.001   29    29      58      1.000   0.066
                       Present          7               65                72                7     7       14              
  Tumor site           Head             18              45                63      0.001     18    19      37      0.015   0.014
                       Body             15              16                31                15    6       21              
                       Tail             3               35                38                3     11      14              
  WBC (^\*^10^9^)      ≤10              32              80                112     0.588     32    34      66      0.674   0.037
                       \>10             4               16                20                4     2       6               
  HGB (g/L)            ≤120             10              25                35      0.828     10    10      20      1.000   0.011
                       \>120            26              71                97                26    26      52              
  PLT (^\*^10^9^)      ≤300             31              77                108     0.613     31    30      61      0.743   0.087
                       \>300            5               19                24                5     6       11              
  ALT (U/L)            ≤40              26              70                96      0.936     26    27      53      0.789   0.092
                       \>40             10              26                36                10    9       19              
  AST (U/L)            ≤40              29              78                107     0.928     29    31      60      0.753   0.073
                       \>40             7               18                25                7     5       12              
  ALP (U/L)            ≤100             18              44                62      0.439     19    18      37      0.816   0.071
                       \>100            18              52                70                17    18      35              
  GGT (U/L)            ≤45              19              37                56      0.166     19    19      38      0.989   −0.001
                       \>45             17              59                76                17    17      34              
  ALB (g/L)            ≤40              4               42                46      \<0.001   4     10      14      0.135   0.110
                       \>40             32              54                86                32    26      58              
  TBIL (umol/L)        ≤20.5            27              76                103     0.640     27    27      54      1.000   0.013
                       \>20.5           9               20                29                9     9       18              
  IBIL (umol/L)        ≤15              32              93                125     0.099     32    36      68      0.115   −0.182
                       \>15             4               3                 7                 4     0       4               
  CRP (ng/L)           ≤3               24              30                54      \<0.001   25    20      45      0.216   0.072
                       \>3              12              66                78                11    16      27              
  CEA (ng/mL)          ≤5               21              40                61      0.116     21    15      36      0.157   0.175
                       \>5              15              56                71                15    21      36              
  CA19-9 (U/ml)        ≤35              9               13                22      0.189     9     5       14      0.372   −0.212
                       \>35             27              83                110               27    30      57              
  HBsAg                Negative         33              88                121     0.974     33    33      66      1.000   0.003
                       Positive         3               8                 11                3     3       6               
  ECGO PS score        0                15              41                56      0.809     15    20      35      0.468   0.165
                       1                19              52                71                19    15      34              
                       2                2               3                 5                 2     1       3               
  Chemotherapy         FOLFIRINOX       21              52                73      0.668     22    23      45      0.796   0.087
                       Gem              15              44                59                14    13      27              

*LN, lymph node metastasis; TNM, tumor-node-metastasis stage; WBC, white blood cell count; PLT, platelet count; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, glutamyl transpeptidase; ALB, albumin; TBIL, total bilirubin; IBIL, indirect bilirubin; CRP, C-reactive protein; HBsAg, hepatitis B surface antigen; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; HBsAg, hepatitis B surface antigen; ECOG PS, Eastern Cooperative Oncology Group (ECOG) performance status*.

Additionally, 132 patients from the SYSUCC were included. The median age for patients in the combination therapy group and the chemotherapy group was 60 years (range, 39--80 years) and 60 years (range, 45--87 years), respectively. Female patients, patients with tumors larger than 4 cm or those with moderately differentiated tumors were commonly seen in both groups. The two groups of patients had substantially balanced variables after the PSM analysis.

OS Comparison Between the Two Groups
------------------------------------

For the SEER series, survival curves for OS were well-separated between the combination therapy and chemotherapy groups. The median OS was 16 months (95% CI, 12--21 months) for the combination therapy group and 9 months (95% CI, not available) for the chemotherapy group ([Figure 2A](#F2){ref-type="fig"}). After the PSM analysis, combination therapy provided a more obvious survival benefit than chemotherapy alone (median OS, 16 months vs. 8 months; 1-year OS rates, 57.1% vs. 32.4%; 3-year OS rates, 30.2% vs. 4.4%; 5-year OS rates, 21.8% vs. 0.9%, *P* \< 0.001, [Figure 2B](#F2){ref-type="fig"}). For the SYSUCC series, survival curves were also well-separated by the different treatments. During the follow-up period, the median OS for the combination therapy group was 21.6 months while the median OS for the chemotherapy group was 7.1 months ([Figure 2C](#F2){ref-type="fig"}). In addition, compared with the chemotherapy group, the combination therapy group experienced significantly higher survival rates (1-year OS rates, 71.4% vs. 30.1%; 2-year OS rates, 53.5% vs. 30.1%, *P* = 0.006, [Figure 2D](#F2){ref-type="fig"}).

![The survival curves of overall survival stratified by treatment strategies for patients with LAPC from SEER dataset before **(A)** and after **(B)** propensity score matching. The survival curves of overall survival stratified by treatment strategies for patients with LAPC from SYSUCC dataset before **(C)** and after **(D)** propensity score matching.](fonc-10-00006-g0002){#F2}

CSS and PFS Comparisons Between the Two Groups
----------------------------------------------

For the SEER series, a total of 2,844 out of 3,348 (84.9%) patients died during the follow-up period, which was more than 80 months. Among these deaths, there were 87 (52.1%) cancer-specific and 17 (10.2%) non-cancer-specific deaths for the combination therapy group and 2,637 (78.8%) cancer-specific and 103 (3.1%) non-cancer-specific deaths for the chemotherapy group. The comparison of cancer-specific mortality and non-cancer-specific mortality is shown in [Figure 3](#F3){ref-type="fig"}. Patients in the chemotherapy group were at higher risk of the cumulative incidence of higher cancer-specific mortality than those in the combination therapy group ([Figure 4A](#F4){ref-type="fig"}). Compared with the chemotherapy group, the combination therapy group experienced significantly higher CSS rates (median CSS, 18 months vs. 8 months; 1-year CSS rates, 59.7% vs. 32.9%; 3-year CSS rates, 32.5% vs. 4.4%; 5-year CSS rates, 27.3% vs. 1.0%, *P* \< 0.001, [Figure 4B](#F4){ref-type="fig"}). For the SYSUCC series, 15 (41.7%) patients experienced disease progression in the combination therapy group, while 42 (43.8%) patients experienced disease progression in the chemotherapy group. After PSM, a higher proportion of patients (19, 52.8%) experienced disease progression in the chemotherapy group compared with that (15, 41.7%) in the combination therapy group. The median PFS for patients was 7.7 months (95% CI, 6.2--10.1 months) in the combination therapy group and 4.1 months (95% CI, 3.1--5.7 months) in the chemotherapy group (*P* \< 0.001, [Figure 4C](#F4){ref-type="fig"}). Similar results were also obtained for patients after PSM (*P* = 0.001, [Figure 4D](#F4){ref-type="fig"}). Patients in the chemotherapy group were 2.67 times more likely to experience tumor progression compared with those in the combination therapy group.

![Cumulative cancer-specific and competing mortalities stratified by treatment strategies for patients with LAPC from SEER dataset before **(A)** and after **(B)** propensity score matching.](fonc-10-00006-g0003){#F3}

![The survival curves of cancer-specific survival stratified by treatment strategies for patients with LAPC from SEER dataset before **(A)** and after **(B)** propensity score matching. The survival curves of progression-free survival stratified by treatment strategies for patients with LAPC from SYSUCC dataset before **(C)** and after **(D)** propensity score matching.](fonc-10-00006-g0004){#F4}

Prognostic Factors for OS, CSS, and PFS
---------------------------------------

Univariate and multivariate analyses were conducted for OS, CSS, and PFS in this study. For the SEER database, a univariate analysis illustrated that age, tumor size, tumor grade, radiotherapy, and chemotherapy combined with IRE were associated with OS and CSS for patients with LAPC. Furthermore, a multivariate model illustrated that chemotherapy combined with IRE was associated with increased OS and CSS. Other significant independent unfavorable prognostic factors for OS included age older than 60 years \[hazard ration (HR) 1.283, 95% CI 1.166--1.412, *P* \< 0.001\], poor tumor differentiation (HR 1.081, 95% CI 1.007--1.160, *P* = 0.032), tumor size larger than 4 cm (HR 1.138, 95% CI 1.056--1.226, *P* = 0.001), and history of radiotherapy (HR 0.608, 95% CI 0.552--0.671, *P* \< 0.001) ([Table 2](#T2){ref-type="table"}). The same factors were identified as significant prognostic factors for CSS in patients with LAPC ([Table 3](#T3){ref-type="table"}).

###### 

Univariate and multivariate analyses of OS in patients.

  **Characteristic**   **Before PSM**         **After PSM**                                                                                                                         
  -------------------- ---------------------- --------------- --------------- --------- ------- --------------- --------- ------- --------------- --------- ------- --------------- ---------
  **SEER DATASET**                                                                                                                                                                  
  Age (years)          ≤60/\>60               1.295           1.193--1.406    \<0.001   1.281   1.180--1.391    \<0.001   1.304   1.186--1.435    \<0.001   1.283   1.166--1.412    \<0.001
  Gender               Female/Male            0.999           0.928--1.075    0.984                             NI        0.994   0.914--1.082    0.895                             NI
  Race                 Black/White/Others     0.949           0.876--1.027    0.194                             NI        0.937   0.855--1.026    0.159                             
  Tumor size (cm)      ≤2/2\~4/\>4            1.137           1.066--1.213    \<0.001   1.148   1.075--1.225    \<0.001   1.135   1.054--1.222    0.001     1.138   1.056--1.226    0.001
  Tumor grade          Well/Moderate/Poor     1.115           1.048--1.186    0.001     1.077   1.012--1.147    0.019     1.119   1.043--1.200    0.002     1.081   1.007--1.160    0.032
  LN metastasis        Absent/Present         1.076           0.996--1.162    0.064                             NI        1.072   0.981--1.172    0.123                             NI
  Tumor site           Head/Body/Tail         0.956           0.909--1.006    0.082                             NI        0.960   0.960--1.016    0.157                             NI
  Radiotherapy         No/Yes                 0.640           0.592--0.691    \<0.001   0.610   0.565--0.660    \<0.001   0.630   0.572--0.694    \<0.001   0.608   0.552--0.671    \<0.001
  Chemotherapy         Without IRE/With IRE   0.428           0.351--0.522    \<0.001   0.369   0.302--0.451    \<0.001   0.403   0.329--0.492    \<0.001   0.370   0.302--0.453    \<0.001
  **SYSUCC DATASET**                                                                                                                                                                
  Age (years)          ≤60/\>60               1.154           0.600--2.222    0.668                             NI        0.889   0.351--0.253    0.804                             NI
  Gender               Female/Male            2.399           1.077--5.343    0.052                             NI        4.630   1.317--16.275   0.017     4.975   1.081--22.891   0.039
  Tumor size (cm)      ≤2/2\~4/\>4            1.657           0.843--3.257    0.143                             NI        2.863   1.021--8.033    0.046     2.012   0.764--5.294    0.157
  Tumor grade          Well/Moderate/Poor     1.182           0.669--2.086    0.565                             NI        1.797   0.680--3.293    0.316                             NI
  LN metastasis        Absent/Present         7.966           3.285--19.315   \<0.001   4.091   1.484--11.278   0.006     7.264   2.220--23.775   0.001     4.799   1.173--19.625   0.029
  Tumor site           Head/Body/Tail         1.317           0.879--1.973    0.182                             NI        1.310   0.700--2.452    0.398                             NI
  WBC (^\*^10^9^)      ≤10/\>10               1.058           0.371--3.019    0.916                             NI        0.463   0.061--3.527    0.457                             NI
  HGB (g/L)            ≤120/\>120             0.852           0.419--1.733    0.659                             NI        1.401   0.461--4.264    0.552                             NI
  PLT (^\*^10^9^)      ≤300/\>300             0.513           0.181--1.455    0.209                             NI        0.484   0.110--2.126    0.337                             NI
  ALT (U/L)            ≤40/\>40               0.929           0.435--1.981    0.848                             NI        1.034   0.365--2.929    0.950                             NI
  AST (U/L)            ≤40/\>40               1.006           0.417--2.428    0.989                             NI        0.623   0.143--2.719    0.529                             NI
  ALP (U/L)            ≤100/\>100             1.686           0.867--3.277    0.124                             NI        1.395   0.549--3.546    0.484                             NI
  GGT (U/L)            ≤45/\>45               1.646           0.840--3.224    0.146                             NI        2.106   0.821--5.400    0.121                             NI
  ALB (g/L)            ≤40/\>40               0.261           0.133--0.515    0.101                             NI        0.437   0.153--1.244    0.121                             NI
  TBIL (umol/L)        ≤20.5/\>20.5           0.712           0.296--1.715    0.449                             NI        0.360   0.083--1.569    0.174                             NI
  IBIL (umol/L)        ≤15/\>15               0.354           0.048--2.589    0.306                             NI        0.043   0.001--77.525   0.411                             NI
  CRP (ng/L)           ≤3/\>3                 3.312           1.582--6.936    0.001     1.741   0.757--4.005    0.192     3.094   1.136--8.428    0.127                             NI
  CEA (ng/mL)          ≤5/\>5                 1.029           0.527--2.011    0.933                             NI        1.264   0.495--3.232    0.624                             NI
  CA19-9 (U/ml)        ≤35/\>35               1.745           0.676--4.507    0.250                             NI        1.714   0.494--5.951    0.396                             NI
  HBsAg                Negative/positive      0.220           0.030--1.610    0.136                             NI        0.264   0.094--0.738    0.011                             NI
  Chemotherapy         Without IRE/with IRE   0.206           0.082--0.515    0.001     0.363   0.132--0.998    0.050     0.264   0.094--0.738    0.011     0.313   0.098--0.992    0.048
  Chemotherapy type    FOLFIRINOX/Gem         0.910           0.648--1.277    0.584                             NI        0.852   0.513--1.414    0.535                             NI

*OS, overall survival; HR, hazard ratio; NI, not included; Other abbreviations as in [Table 1](#T1){ref-type="table"}*.

###### 

Univariate and multivariate analyses of CSS and PFS in patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristic**   **Before PSM**         **After PSM**                                                                                                                     
  -------------------- ---------------------- --------------- -------------- --------- ------- -------------- --------- ------- -------------- --------- ------- -------------- ---------
  **CSS**\                                                                                                                                                                      
  **SEER DATASET**                                                                                                                                                              

  Age (years)          ≤60/\>60               1.282           1.179--1.394   \<0.001   1.269   1.167--1.381   \<0.001   1.278   1.160--1.408   \<0.001   1.258   1.142--1.387   \<0.001

  Gender               Female/Male            0.998           0.926--1.076   0.957                            NI        0.988   0.906--1.077   0.784                            NI

  Race                                        0.963           0.888--1.045   0.368                            NI        0.955   0.870--1.048   0.328                            NI

  Tumor size (cm)      ≤2/2\~4/\>4            1.128           1.056--1.204   \<0.001   1.161   1.086--1.243   \<0.001   1.125   1.043--1.213   0.002     1.129   1.046--1.219   0.002

  Tumor grade          Well/Moderate/Poor     1.114           1.046--1.187   0.001     1.167   1.082--1.260   \<0.001   1.116   1.039--1.200   0.003     1.079   1.004--1.161   0.040

  LN metastasis        Absent/Present         1.090           1.007--1.179   0.032     1.069   0.988--1.157   0.099     1.088   0.994--1.192   0.069                            NI

  Tumor site           Head/Body/Tail         0.950           0.902--1.000   0.050     0.884   0.830--0.941   \<0.001   0.951   0.897--1.009   0.095                            NI

  Radiotherapy         No/Yes                 0.647           0.598--0.700   \<0.001   0.614   0.567--0.664   NI        0.635   0.575--0.701   \<0.001   0.611   0.553--0.675   \<0.001

  Chemotherapy         Without IRE/With IRE   0.372           0.300--0.462   \<0.001   0.332   0.267--0.413   \<0.001   0.351   0.283--0.437   \<0.001   0.323   0.260--0.403   \<0.001

  **PFS**\                                                                                                                                                                      
  **SYSUCC DATASET**                                                                                                                                                            

  Age (years)          ≤60/\>60               0.690           0.410--1.163   0.164                            NI        0.728   0.379--1.397   0.340                            NI

  Gender               Female/Male            1.513           0.868--2.639   0.144                            NI        1.692   0.864--3.315   0.125                            NI

  Tumor size (cm)      ≤2/2\~4/\>4            1.375           0.848--2.232   0.196                            NI        1.537   0.827--2.856   0.174                            NI

  Tumor grade          Well/Moderate/Poor     1.271           0.814--1.986   0.291                            NI        1.226   0.724--2.077   0.447                            NI

  LN metastasis        Absent/Present         2.867           1.588--5.176   \<0.001   2.380   1.269--4.460   0.007     3.190   1.526--6.672   0.002     4.170   1.898--9.163   \<0.001

  Tumor site           Head/Body/Tail         1.281           0.930--1.763   0.130                            NI        1.388   0.900--2.142   0.138                            NI

  WBC (^\*^10^9^)      ≤10/\>10               1.282           0.628--2.616   0.495                            NI        0.995   0.315--2.823   0.993                            NI

  HGB (g/L)            ≤120/\>120             1.155           0.642--2.077   0.631                            NI        1.311   0.620--2.774   0.479                            NI

  PLT (^\*^10^9^)      ≤300/\>300             0.819           0.412--1.628   0.570                            NI        0.512   0.198--1.323   0.167                            NI

  ALT (U/L)            ≤40/\>40               0.753           0.413--1.374   0.355                            NI        0.733   0.346--1.550   0.416                            NI

  AST (U/L)            ≤40/\>40               0.775           0.381--1.579   0.483                            NI        0.841   0.350--2.018   0.697                            NI

  ALP (U/L)            ≤100/\>100             1.024           0.614--1.709   0.927                            NI        0.956   0.506--1.808   0.890                            NI

  GGT (U/L)            ≤45/\>45               0.870           0.518--1.459   0.597                            NI        0.729   0.376--1.411   0.348                            NI

  ALB (g/L)            ≤40/\>40               0.775           0.445--1.349   0.367                            NI        0.750   0.354--1.587   0.452                            NI

  TBIL (umol/L)        ≤20.5/\>20.5           0.544           0.266--1.112   0.095                            NI        0.419   0.174--1.008   0.052                            NI

  IBIL (umol/L)        ≤15/\>15               1.116           0.445--2.804   0.815                            NI        0.796   0.244--2.600   0.705                            NI

  CRP (ng/L)           ≤3/\>3                 1.605           0.922--2.795   0.095                            NI        1.419   0.696--2.893   0.336                            NI

  CEA (ng/mL)          ≤5/\>5                 1.123           0.668--1.890   0.662                            NI        1.221   0.643--2.320   0.542                            NI

  CA19-9 (U/ml)        ≤35/\>35               1.965           0.927--4.167   0.078                            NI        3.258   1.148--9.247   0.027     1.191   0.394--3.606   0.757

  HBsAg                Negative/Positive      0.501           0.181--1.393   0.185                            NI        0.805   0.246--2.634   0.719                            NI

  Chemotherapy         Without IRE/With IRE   0.357           0.197--0.649   0.001     0.491   0.251--0.960   0.038     0.350   0.180--0.678   0.002     0.305   0.146--0.638   0.002

  Chemotherapy type    FOLFIRINOX/Gem         1.006           0.781--1.298   0.960                            NI        0.996   0.719--1.380   0.980                            NI
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*CSS, cancer-specific survival; PFS, progression-free survival; HR, hazard ratio; Other abbreviations as in [Table 1](#T1){ref-type="table"}*.

The data from the SYSUCC series were also used to analyze the prognostic factors of OS and PFS. Gender, tumor size, lymph node (LN) metastasis and chemotherapy plus IRE were associated with OS in patients with LAPC. In addition, after a stepwise removal of variables in the multivariate analysis, male gender (HR 4.975, 95% CI 1.081--22.891, *P* = 0.039), presence of LN metastasis (HR 4.799, 95% CI 1.173--19.625, *P* = 0.029), and chemotherapy plus IRE (HR 0.313, 95% CI 0.098--0.992, *P* = 0.048) were identified as independent prognostic factors for OS ([Table 2](#T2){ref-type="table"}). A multivariate analysis revealed that chemotherapy plus IRE was identified as an independent favorable prognostic factor for PFS in patients in both the entire cohort and the matched cohort ([Table 3](#T3){ref-type="table"}).

Discussion {#s4}
==========

Previous studies have shown a survival benefit for IRE plus conventional treatment in patients with LAPC ([@B6], [@B7], [@B21]). Most of the aforementioned studies were single-arm studies. There was one study that suggested that treatment with IRE combined with chemotherapy increased the median OS of patients with LAPC compared to conventional treatments ([@B22]). However, all these studies contained limited patient cohorts or lacked external validation. In contrast, another small cohort and single-center study showed no significant survival benefit from IRE after induction chemotherapy ([@B8]). The significance of the lack of rigorous quality assessments in these studies in regard to their negative outcomes is unknown. Multiple smaller studies with varying chemotherapy regimens have provided mixed results ([@B6], [@B8], [@B23]). Therefore, there has been no strong evidence for the survival benefit of IRE combined with chemotherapy in LAPC patients. The current study compared the efficacy between IRE plus chemotherapy and chemotherapy in patients with LAPC based on the cohorts from the SEER database and the SYSUCC database, a "real-world" dataset. To our knowledge, this is the largest study evaluating the role of IRE combined with chemotherapy in patients with LAPC. Our analysis provided evidence that patients with LAPC who were treated with IRE combined with chemotherapy had a more obvious survival benefit compared with those who were treated with chemotherapy alone.

In this study, all patients in the SYSUCC dataset received standard chemotherapy, including GEM-based chemotherapy or FOLFIRINOX-based chemotherapy. In addition, gemcitabine-based chemotherapy has been the first-line therapy for advanced pancreatic cancer since the positive survival results of gemcitabine-based chemotherapy were revealed in 1997 ([@B24]). It can be assumed that the chemotherapy regimen, which was mainly GEM-based chemotherapy for patients from the SEER database, was uniform and recommended for patients with LAPC during this time period ([@B24], [@B25]). The median OS was 16 and 21.6 months for patients after IRE combined with chemotherapy in the SEER and SYSUCC datasets, respectively. The median OS was similar to that from a study conducted by Huang et al. ([@B26]) and was significantly higher than that of patients after chemotherapy alone (8.0 months for the SEER patients and 7.1 months for the SYSUCC patients). In addition, the SEER patients had a long follow-up period, and it was shown that combination therapy was superior to chemotherapy alone with respect to not only 5-year OS rates but also 5-year CSS rates for all enrolled patients even though larger proportions of patients in the chemotherapy group received radiotherapy. After the PSM analysis, the advantages of survival benefits in terms of OS and CSS from combination therapy were even more obvious, compared with those from chemotherapy alone in both the SEER and SYSUCC patients. In the present study, 21 patients received FOLFIRINOX-based chemotherapy in the SYSUCC cohort, although patients with LAPC had significantly improved survival from the newest modified FOLFIRINOX-based chemotherapy ([@B27]). FOLFIRINOX-based chemotherapy became popular more recently. Only a proportion of patients received FOLFIRINOX-based chemotherapy in this study. The absence of uniform protocols and the intolerance to the full dosages of FOLFIRINOX-based chemotherapy might partially explain the unsatisfactory results for chemotherapy in this study. In addition, cross-study comparisons were also conducted. Studies conducted by Krishnan et al. ([@B28]) and Huguet et al. ([@B29]) showed that chemotherapy combined with radiotherapy contributed to the median OS, which was nearly 12 months for patients with LAPC, and significantly lower than that of patients who received IRE combined with chemotherapy. These comparisons further consolidated the survival advantages of combination therapy over chemotherapy alone. In addition, there was a disparity in the survival between the SEER and SYSUCC patients, the development of chemotherapy regimens and technology of IRE may ultimately improve the survival of LAPC patients after combination therapy. However, a survival benefit of IRE combined with chemotherapy was observed in patients with LAPC who received any type of chemotherapy. Radiotherapy was also shown as a favorable prognostic factor for both OS and CSS for patients with LAPC after IRE plus chemotherapy therapy. The enhanced local and systemic control of diseases further improved survival outcomes, showing that maybe IRE was an effective supplement to the standard therapy for LAPC patients.

Tumor progression was commonly observed in patients with LAPC even after treatment. Compared with the 19 out of 36 (52.8%) patients who experienced disease progression after chemotherapy, 15 out of 36 (41.7%) patients experienced disease progression after IRE combined with chemotherapy during the follow-up period. Compared with chemotherapy alone, IRE combined with chemotherapy resulted in significantly longer PFS. IRE assists the chemotherapy delivery to the tumor by disrupting the dense stroma of pancreatic cancer ([@B30], [@B31]). Another mechanism of IRE is the formation of nanoscale micropores in the lipid bilayer of cell membranes increases its permeability to macromolecules, including chemical ([@B12]). Moreover, in IRE treatment, an electric field surrounds the entire tumor without causing thermal damage to important nearby structures ([@B12]). Maybe these mechanisms help to explain the synergism of IRE and chemotherapy compared with chemotherapy alone. In addition, as a local destructive treatment, maybe IRE could only control the local disease, the subsequent chemotherapy was needed to adequately control microscopic disease. IRE combined with chemotherapy created a synergistic effect to decrease the local recurrence rates and to lengthen PFS for patients with LAPC.

Similar to another study with a large cohort conducted by Martin et al. ([@B32]), which was a single-arm study showing an encouraging 24.9-month median OS and 12.4-month median PFS, our study provided new data illustrating the survival benefit from IRE combined with chemotherapy. In contrast to our study, 25% of patients in Martin\'s study underwent resection and IRE margin accentuation. Our study focused on patients which were not suitable for concomitant resection and aimed to provide new insights on this combination therapy for patients with LAPC. In addition, with the large cohort from the SEER database and the external cohort from the SYSUCC database, a survival benefit for IRE combined with chemotherapy was clearly shown, which suggests that IRE combined with chemotherapy was an effective multimodal approach and assisted both local tumor reduction and systemic control of the disease in patients with LAPC.

This study has limitations. First, there was potential selection bias in this retrospective trial. The PSM analysis decreased the selection bias associated with the variables incorporated into the comparisons, but these biases could not be completely removed. The SEER database provided a sufficient sample size to eliminate heavily selected observations without reducing power to robustly evaluate treatment effects. However, despite such matching, residual confounding by indication due to unmeasured variables cannot be ruled out. Second, detailed information on chemotherapy, including the dose and course of chemotherapy, and some important hematological indexes, such as CA19-9 and CEA, are not available in the SEER database. Third, there was no information on the comorbidities or performance status of the patients in this study. Although strict inclusion criteria were followed and only patients who received IRE treatment were included, the sample size of patients from the SYSUCC database was small, and the follow-up period was not long enough to make definitive conclusions. Therefore, the survival benefit of IRE in patients with LAPC needs to be validated in another large cohort.

In conclusion, compared with chemotherapy alone, IRE combined with chemotherapy contributed to better long-term survival in patients with LAPC. A randomized clinical trial comparing the efficacy of IRE and chemotherapy is therefore warranted.
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